Physician profile
Aaron Bennion
NPI 1659709848
$4,952.52
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,567 · 2022: $1,897 · 2023: $1,285 · 2024: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,488.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $827.49 | 2021-2023 | |
| Actelion Pharmaceuticals US, INC. | $784.66 | 2021-2023 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $651.76 | 2021-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $507.60 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $482.24 | 2023-2024 | |
| Amgen INC. | $443.40 | 2021-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $214.31 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $207.57 | 2021-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $154.76 | 2021-2023 | |
| Amarin Pharma, INC. | $113.36 | 2021-2022 | |
| Boston Scientific Corporation | $93.24 | 2021-2023 | Watchman Access System |
| Merck Sharp & Dohme LLC | $88.73 | 2021-2023 | Verquvo |
| Abbott Laboratories | $68.01 | 2021-2022 | |
| Abbvie INC. | $49.68 | 2023 | |
| Heartflow, INC. | $35.15 | 2023 | Ffrct |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $33.92 | 2023 | Arcalyst |
| United Therapeutics Corporation | $32.50 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $24.77 | 2022-2023 | Seglentis, Livalo |
| Esperion Therapeutics, INC. | $24.02 | 2021 | |
| Vifor Pharma, INC. | $22.13 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.19 | 2021 | |
| Amryt Pharma Holdings LTD | $17.74 | 2022 | |
| Altathera Pharmaceuticals LLC | $16.03 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.73 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.08 | 2021 | |
| Chiesi USA, INC. | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Bennion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.